Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Article Details
- CitationCopy to clipboard
Zimhony O, Vilcheze C, Arai M, Welch JT, Jacobs WR Jr
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Antimicrob Agents Chemother. 2007 Feb;51(2):752-4. Epub 2006 Nov 13.
- PubMed ID
- 17101678 [ View in PubMed]
- Abstract
The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in bacilli treated with n-propyl pyrazinoate, 94% in bacilli treated with 5-chloro-pyrazinamide, and 97% in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Pyrazinamide Fatty acid synthetase Protein Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) YesInhibitorDetails